-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on NewAmsterdam Pharma Co, Maintains $40 Price Target

Benzinga·06/12/2025 10:29:49
Listen to the news
Needham analyst Serge Belanger reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $40 price target.